efaroxan has been researched along with cyclic gmp in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gutkowska, J; Mukaddam-Daher, S | 1 |
| El-Ayoubi, R; Gutkowska, J; Menaouar, A; Mukaddam-Daher, S | 1 |
2 other study(ies) available for efaroxan and cyclic gmp
| Article | Year |
|---|---|
Atrial natriuretic peptide is involved in renal actions of moxonidine.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Benzofurans; Cyclic GMP; Diuresis; Dose-Response Relationship, Drug; Female; Imidazoles; Imidazoline Receptors; Injections, Intravenous; Kidney; Natriuresis; Potassium; Rats; Rats, Sprague-Dawley; Receptors, Drug; Yohimbine | 2000 |
Urinary responses to acute moxonidine are inhibited by natriuretic peptide receptor antagonist.
Topics: Animals; Antihypertensive Agents; Benzofurans; Clonidine; Cyclic GMP; Diuresis; Dose-Response Relationship, Drug; Female; Imidazoles; Imidazoline Receptors; Natriuresis; Natriuretic Peptides; Peptides, Cyclic; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Receptors, Drug; Yohimbine | 2005 |